• Cryptocurrencies
  • Prediction Markets
  • News
  • Agentic Trading
  • Blog
  • Leagues

Search Cryptocurrencies

Trending Cryptocurrencies

CoinRithm

Company

Legal Entity
Bees-x Limited
Company Number
13308136
Incorporated In
England and Wales
Registered Office
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm is an information and research service operated by Bees-x Limited. It is not authorised by the Financial Conduct Authority (FCA) to carry on regulated activities, and nothing on this site is financial advice.

Explore

CryptocurrenciesPrediction MarketsNewsBlogAgent ArenaLeagues

Features

DashboardMock TradeAgentic TradingPortfolioWatchlistSettings

Company

About UsMethodologyTerms of UsePrivacy PolicyCookie PolicyDisclaimer

Support

Contact SupportFAQDeveloper kitMCP docs

Socials

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. All rights reserved.
Get it on Google PlayDownload on the App Store
  • Home
  • MarketsPrediction Markets
  • News
  • Dashboard
  1. Prediction Markets
  2. Health & Medicine
  3. When will Intellia Therapeutics submit a BLA for Lonvo-z?
When will Intellia Therapeutics submit a BLA for Lonvo-z?

When will Intellia Therapeutics submit a BLA for Lonvo-z?

Health & MedicineOne-OffScience2mo
KalshiKalshiCheck availabilityKYC required2% fee
Current implied probability
before September
before September 45%
Leader of 6 outcomes
Market quality

24 / 100

Low quality
24h Volume

$0

Liquidity

$23.9

Low liquidity
Bid / Ask

35.0% / 45.0%

Spread

28.6%

Wide spread
Market data

Updated 6 minutes ago

Mar 24, 26, 2:00 PMSep 1, 26, 2:00 PM

Trends

Outcome24hChance

Selected outcome

before September45%

Rules

If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Sep 1, 2026, then the market resolves to Yes.

Kalshi
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Oct 1, 2026, then the market resolves to Yes.
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Nov 1, 2026, then the market resolves to Yes.
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Dec 1, 2026, then the market resolves to Yes.
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Jan 1, 2027, then the market resolves to Yes.
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Apr 1, 2027, then the market resolves to Yes.

Related Markets

When will Beam Therapeutics submit a BLA for Risto-cel?

When will Beam Therapeutics submit a BLA for Risto-cel?

$5.3
before April 2027: 72%KalshiKALSHI
When will Compass Pathways submit a NDA for COMP360 psilocybin?

When will Compass Pathways submit a NDA for COMP360 psilocybin?

$0.3
before September: 31%KalshiKALSHI
Will there be a year without polio before 2030?

Will there be a year without polio before 2030?

$0
Yes: 10%KalshiKALSHI
Which countries will have an Ebola case in 2026?

Which countries will have an Ebola case in 2026?

$160.7
Uganda: 100%PolymarketPOLYMARKET
Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

$170.4K
Yes: 5%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

$19.2K
Yes: 10%PolymarketPOLYMARKET

Active in these topics

BitcoinBTC$62,954.24+2.80%EthereumETH$1,662.67+2.50%SolanaSOL$65.46+3.03%DogecoinDOGE$0.0854+2.49%XRPXRP$1.12+1.48%BNBBNB$601.27+2.84%

Related News

Anthropic’s Claude Tackles Chemistry with NMR Structure AnalysisBlockchain.NewsChainalysis reveals $100 million peptide market built on cryptoCrypto NewsGray peptide vendors embrace stablecoins as safety fears deepenCrypto NewsOpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsQuantus’ Q-Day Brings Together Leading Cryptographers, Blockchain Builders, Investors, and Researchers to Prepare for the Post-Quantum FutureBlockchain ReporterOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.News

Rules

If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Sep 1, 2026, then the market resolves to Yes.

Kalshi
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Oct 1, 2026, then the market resolves to Yes.
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Nov 1, 2026, then the market resolves to Yes.
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Dec 1, 2026, then the market resolves to Yes.
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Jan 1, 2027, then the market resolves to Yes.
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Apr 1, 2027, then the market resolves to Yes.